Genomic biomarkers androgen pathway and prostate cancer

Franca D'Amico, Michela Biancolella, Katia Margiotti, Juergen K V Reichardt, Giuseppe Novelli

Research output: Contribution to journalArticlepeer-review

Abstract

Prostate cancer is the most frequent male malignancy diagnosed in western countries and the second leading cause of cancer-related deaths. The growth and function of the prostate gland depends on androgens. Owing to the importance of androgens in prostate development, genes involved in androgen biosynthesis and metabolism have been extensively studied. In this review, we address recent progress toward the use of inherited and acquired genetic variants to predict susceptibility and clinical outcomes of prostate cancer patients. Many of these genetic variants involve several genes related to the biosynthesis and metabolism of androgens, such as steroid-5-α-reductase, α polypepticle 2 (SRD5A2), cytochrome P450 (CYP) 19A1, CYP17A1, hydroxy-δ-5-steroid dehydrogenase, 3 β- and steroid δ-isomerase 2 (HSD3B2) and androgen receptor (AR). With increasing knowledge, it may be possible to distinguish indolent from aggressive prostate tumors by molecular fingerprinting. Furthermore, with the emergence of new investigative tools, such as microarray platforms and comparative genomic hybridization (CGH) array, a variety of new genomic biomarkers will be available in the future to provide accurate prognostic and monitoring solutions for individualized patient care.

Original languageEnglish
Pages (from-to)645-661
Number of pages17
JournalPharmacogenomics
Volume8
Issue number6
DOIs
Publication statusPublished - Jun 2007

Keywords

  • Androgen pathway
  • Androgen receptor
  • CYP17
  • CYP19
  • HSD3B2
  • Prostate cancer
  • SNP
  • Somatic mutation
  • SRD5A
  • Steroid-5α-reductase

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Genomic biomarkers androgen pathway and prostate cancer'. Together they form a unique fingerprint.

Cite this